Five‐Year Survival in EGFR‐Mutant Metastatic Lung Adenocarcinoma Treated with EGFR‐TKIs

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Thoracic Oncology

• Publication date

  2016-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jtho.2015.12.103PMID 26724471PMCID PMC4979601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Global surveillance of cancer survival 1995-2009: analysis of individual data for 25,676,887 patients from 279 population-based registries in 67 countries (CONCORD-2).

  2015cited by this paper
• Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

  2015cited by this paper
• Delay of treatment change after objective progression on first‐line erlotinib in epidermal growth factor receptor‐mutant lung cancer

  2015cited by this paper
• 1223OASPIRATION: FIRST-LINE ERLOTINIB (E) UNTIL AND BEYOND RECIST PROGRESSION (PD) IN ASIAN PATIENTS (PTS) WITH EGFR MUTATION-POSITIVE (MUT+) NSCLC.

  2014cited by this paper
• Letter to the editor on 'Phase III trial of concurrent thoracic radiotherapy with either first- or third-cycle chemotherapy for limited-disease small cell lung cancer'.

  2014cited by this paper
• Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

  2014cited by this paper
• Clinical study on long-term overall survival of advanced non-small-cell lung cancer patients treated with Chinese medicine and western medicine

  2014cited by this paper
• Is there any predictor for clinical outcome in EGFR mutant NSCLC patients treated with EGFR TKIs?

  2014cited by this paper
• CNS metastases in non-small-cell lung cancer: current role of EGFR-TKI therapy and future perspectives.

  2013cited by this paper
• Clinical factors predictive of long-term survival in advanced non-small cell lung cancer.

  2013cited by this paper
• Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

  2013cited by this paper
• Meta-analysis of EGFR kinase inhibitors: not always greater than the sum of its parts.

  2013cited by this paper
• Updated overall survival results from a randomized phase III trial comparing gefitinib with carboplatin-paclitaxel for chemo-naïve non-small cell lung cancer with sensitive EGFR gene mutations (NEJ002).

  2013cited by this paper
• A retrospective analysis of 335 Japanese lung cancer patients who responded to initial gefitinib treatment.

  2013cited by this paper
• Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: a meta-analysis.

  2013cited by this paper
• Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.

  2013cited by this paper
• Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer.

  2012cited by this paper
• Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth factor receptor (EGFR).

  2012cited by this paper
• The Impact of Initial Gefitinib or Erlotinib versus Chemotherapy on Central Nervous System Progression in Advanced Non–Small Cell Lung Cancer with EGFR Mutations

  2012cited by this paper
• Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

  2012cited by this paper
• Factors associated with long‐term survival of patients with advanced non‐small cell lung cancer

  2012cited by this paper
• Long-term survival rates of patients with stage IIIB and IV non-small cell lung cancer treated with cisplatin plus vinorelbine or gemcitabine

  2012cited by this paper
• Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.

  2011cited by this paper
• Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).

  2011cited by this paper
• Long-term survivors of more than 5 years in advanced non-small cell lung cancer.

  2010cited by this paper
• Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.

  2010cited by this paper
• Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or Erlotinib

  2010cited by this paper
• F1000 highlights

  2010cited by this paper
• Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

  2010cited by this paper
• Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer.

  2010cited by this paper
• Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

  2010cited by this paper
• Screening for epidermal growth factor receptor mutations in lung cancer.

  2009cited by this paper
• F1000 highlights

  2009influential reference
• Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

  2009cited by this paper
• Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer.

  2008influential reference
• Effects of Erlotinib in EGFR Mutated Non-Small Cell Lung Cancers with Resistance to Gefitinib

  2008cited by this paper
• Long-term survivors after chemotherapy in advanced non-small cell lung cancer.

  2007cited by this paper
• Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

  2006cited by this paper
• Clinical Course of Patients with Non–Small Cell Lung Cancer and Epidermal Growth Factor Receptor Exon 19 and Exon 21 Mutations Treated with Gefitinib or Erlotinib

  2006cited by this paper
• Exon 19 Deletion Mutations of Epidermal Growth Factor Receptor Are Associated with Prolonged Survival in Non–Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

  2006cited by this paper
• SEER Cancer Statistics Review, 1975-2003

  2006cited by this paper
• Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers.

  2006cited by this paper
• Long-term survivors in stage IV non-small cell lung cancer.

  2005cited by this paper
• Current management of brain metastases, with a focus on systemic options.

  2005cited by this paper
• Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).

  2005cited by this paper
• Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations.

  2005cited by this paper
• Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence.

  2005cited by this paper
• Erlotinib in previously treated non-small-cell lung cancer.

  2005cited by this paper
• Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

  2004cited by this paper
• Anticancer drugs: To the rescue?

  2004cited by this paper
• EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

  2004cited by this paper
• Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer

  2004cited by this paper
• Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

  2003cited by this paper
• Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.

  2003cited by this paper
• Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.

  2002influential reference

• COL11A1 promotes lung adenocarcinoma progression via PI3K/AKT/mTOR pathway: mechanistic insights and development of a COL11A1-related prognostic signature

  2026cites this paper
• Five-year survival of patients with non-small cell lung cancer treated with alkalization therapy

  2026cites this paper
• Clinical Impact of EGFR Mutation Subtypes on Treatment Outcomes in Advanced Non-Small Cell Lung Cancer: An Austrian Real-World Study

  2026cites this paper
• A succinylation-related prognostic model for predicting lung adenocarcinoma prognosis and guiding immunotherapy

  2026cites this paper
• Integrating zinc homeostasis network and immune landscape: a five-gene prognostic framework for precision oncology in lung adenocarcinoma

  2026cites this paper
• Integrated ICD-based subtyping and prognostic model reveal KCNN4 as a novel therapeutic target in NSCLC.

  2026cites this paper
• Serum markers for prognostic value of EGFR-TKI in lung adenocarcinoma with bone metastases: a retrospective study

  2026cites this paper
• Persistent Corneal Epithelial Defects Associated with Afatinib Therapy in a Patient with Non–Small Cell Lung Cancer: A Case Report

  2025cites this paper
• Identification of CAV1 and CDH5 as potential diagnostic and prognostic biomarkers in lung adenocarcinoma

  2025cites this paper
• LncRNA RP11-297P16.4 Promotes the Invasion and Metastasis of Non-Small-Cell Lung Carcinoma by Targeting the miR-145-5p/MMP-2/9 Axis

  2025cites this paper
• Significance of LRFN4 in prognosis and tumor microenvironment of lung adenocarcinoma

  2025cites this paper
• Prognostic model based on KCNK family genes for predicting prognosis and immunotherapy response in lung adenocarcinoma patients.

  2025cites this paper
• Addition of bevacizumab to gefitinib plus chemotherapy as first-line therapy in EGFR L858R mutate advanced non-small cell lung cancer patients

  2025cites this paper
• Prevalence and therapeutic response of EGFR T790I mutation in NSCLC patients with acquired resistance to EGFR-TKIs: a retrospective cohort study

  2025cites this paper
• Mixed radiation with different doses induces CCL17 to recruit CD8+T cell to exert anti-tumor effects in non-small cell lung cancer

  2025cites this paper
• Survival analysis and prognostic factors of diffuse bilateral intrapulmonary metastases in patients with non-small cell lung cancer

  2025cites this paper
• Prognostic Factors in EGFR Mutation‐positive Patients With Bone Metastases from Lung Adenocarcinoma

  2025cites this paper
• E2F1-autophagy-ALDH1A1 axis enhances self-renewal and drug resistance of lung cancer stem-like cells in a p53-dependent manner

  2025cites this paper
• Senescence-associated secretory phenotype in lung cancer: remodeling the tumor microenvironment for metastasis and immune suppression

  2025cites this paper
• Time-to-Event Modeling for Survival Prediction of Osimertinib as the First- and Second-Line Therapy

  2025cites this paper
• Lung Cancer—Epidemiology, Pathogenesis, Treatment and Molecular Aspect (Review of Literature)

  2025cites this paper
• Role of TP53 Mutations and EGFR Amplification in Risk Stratification of Early‐Stage EGFR‐Mutated Non‐Small Cell Lung Cancer With Immunohistochemistry as a Surrogate Marker

  2025cites this paper
• High-fidelity Cas9-mediated targeting of KRAS driver mutations restrains lung cancer in preclinical models

  2025cites this paper
• Challenges and considerations of DNA methylation markers in peripheral blood mononuclear cells for early screening of lung adenocarcinoma

  2025cites this paper
• Optimizing management of stage IV EGFR mutant non‐small cell lung cancer in Asia: An expert opinion

  2025cites this paper
• Integrative spatial analysis reveals tumor heterogeneity and immune colony niche related to clinical outcomes in small cell lung cancer.

  2025cites this paper
• Hepatotoxicity and efficacy associated with first- and new-generation EGFR-TKIs in patients with NSCLC: a systematic review and meta-analysis

  2025cites this paper
• Treatment Outcomes From Erlotinib and Gefitinib in Advanced Epidermal Growth Factor Receptor–Mutated Nonsquamous Non–Small Cell Lung Cancer in Aotearoa New Zealand From 2010 to 2020: Nationwide Whole-of-Patient-Population Retrospective Cohort Study

  2025cites this paper
• Association between EGFR mutation types and incidence of brain metastases in postoperative patients with stage I–III NSCLC

  2025cites this paper
• Research Progress on MAZ in Malignant Tumors

  2025cites this paper
• Diverse clinical outcomes for the EGFR‑mutated and ALK‑rearranged advanced non‑squamous non‑small cell lung cancer

  2025cites this paper
• Engineered flower-shaped MXene-copper nanowire composite facilitate mechanically tuned and sensitive field-effect transistors in miniaturized portable devices toward noninvasive NSCLC prognostic monitoring

  2025cites this paper
• Multivariable model for predicting 5-year survival in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective study

  2025influential citation
• An exosomes-related lncRNA prognostic model correlates with the immune microenvironment and therapy response in lung adenocarcinoma

  2024cites this paper
• Identification of PRODH as a mitochondria- and angiogenesis-related biomarker for lung adenocarcinoma

  2024cites this paper
• Non-Small Cell Lung Cancer, Version 4.2024.

  2024cites this paper
• Prognostic implications of combining EGFR‐TKIs and radiotherapy in Stage IV lung adenocarcinoma with 19‐Del or 21‐L858R mutations: A real‐world study

  2024cites this paper
• Real-World Analysis of Post-Progression Treatment Patterns and Outcomes for EGFR Mutation-Positive Patients Treated with First-Line Osimertinib

  2024cites this paper
• Integrated analysis highlights the significance role of ITGAL in lung adenocarcinoma

  2024cites this paper
• Ensartinib in the treatment of anaplastic lymphoma kinase‐positive locally advanced or metastatic patients with lung squamous or adenosquamous carcinoma: A real‐world, retrospective study

  2024cites this paper
• MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?

  2024cites this paper
• Clinical efficacy and safety analysis of aumolertinib in real-world treatment of EGFR-mutated advanced non-small-cell lung cancer

  2024cites this paper
• Therapeutic drug monitoring of osimertinib in EGFR mutant non‐small cell lung cancer by dried blood spot and plasma collection: A pilot study

  2024cites this paper
• Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC

  2024influential citation
• Discovery of a novel ROS-based signature for predicting prognosis and immunosuppressive tumor microenvironment in lung adenocarcinoma

  2024cites this paper
• Efficacy analysis of immunotherapy‑based combinations for patients with EGFR‑mutant advanced non‑small cell lung cancer after TKI failure

  2024cites this paper
• Long-Term Outcomes in Patients with EGFR Positive Lung Adenocarcinoma and Subgroup Analysis Based on Presence of Liver Metastases

  2024cites this paper
• Anti-EGFR aptamer exhibits direct anti-cancer effects in NSCLC cells harboring EGFR L858R mutations

  2024cites this paper
• MRI radiomics for predicting intracranial progression in non-small-cell lung cancer patients with brain metastases treated with epidermal growth factor receptor tyrosine kinase inhibitors.

  2024cites this paper
• Cymensifin A: a promising pharmaceutical candidate to defeat lung cancer via cellular reactive oxygen species-mediated apoptosis

  2024cites this paper
• The GJB3 correlates with the prognosis, immune cell infiltration, and therapeutic responses in lung adenocarcinoma

  2024cites this paper
• Effect of fermentation on the constituents in the branches and leaves of Taxus media and non-small cell lung cancer

  2024cites this paper
• Perioperative immunotherapy for patients with EGFR mutant non-small cell lung cancer: Unexpected potential benefits.

  2024cites this paper
• Nivolumab Plus Chemotherapy in Epidermal Growth Factor Receptor–Mutated Metastatic Non–Small-Cell Lung Cancer After Disease Progression on Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Final Results of CheckMate 722

  2024cites this paper
• Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201.

  2024cites this paper
• Novel Spatial Approaches to Dissect the Lung Cancer Immune Microenvironment

  2024cites this paper
• HDAC1 and FOXK1 mediate EGFR-TKI resistance of non-small cell lung cancer through miR-33a silencing

  2024cites this paper
• LncRNA PRKCA-AS1 promotes LUAD progression and function as a ceRNA to regulate S100A16 by sponging miR-508-5p

  2024cites this paper
• A multimodal knowledge-enhanced whole-slide pathology foundation model

  2024cites this paper
• Implementation of an ISO 15189 accredited next generation sequencing service for cell-free total nucleic acid (cfTNA) analysis to facilitate driver mutation reporting in blood: the experience of a clinical diagnostic laboratory

  2024cites this paper
• Revealing the active ingredients and mechanism of P. sibiricumm in non-small-cell lung cancer based on UPLC-Q-TOF-MS/MS, network pharmacology, and molecular docking

  2024influential citation
• Low Expression of SCN4B Predicts Poor Prognosis in Non-Small Cell Lung Cancer.

  2024cites this paper
• Clinical outcomes for immune checkpoint inhibitors plus chemotherapy in non-small-cell lung cancer patients with uncommon driver gene alterations

  2024cites this paper
• Understanding the treatment response and resistance to targeted therapies in non-small cell lung cancer: clinical insights and perspectives

  2024cites this paper
• Arsenic trioxide elicits anti-tumor activity by inhibiting polarization of M2-like tumor-associated macrophages via Notch signaling pathway in lung adenocarcinoma.

  2023cites this paper
• Anoikis-related gene signatures predict prognosis of lung adenocarcinoma patients and reveal immune infiltration

  2023cites this paper
• Additional local therapy before disease progression for EGFR-mutated advanced lung cancer: a systematic review and meta-analysis

  2023cites this paper
• A ferroptosis‐related LncRNAs signature for predicting prognoses and screening potential therapeutic drugs in patients with lung adenocarcinoma: A retrospective study

  2023cites this paper
• A novel APA-based prognostic signature may predict the prognosis of lung adenocarcinoma in an East Asian population

  2023cites this paper
• FOXM1 and CENPF are associated with a poor prognosis through promoting proliferation and migration in lung adenocarcinoma

  2023cites this paper
• Analysis of prognostic factors and establishment of prediction model of lung adenocarcinoma based on SEER database

  2023cites this paper
• ELOVL6 is associated with immunosuppression in lung adenocarcinoma through bioinformatics analysis

  2023cites this paper
• Efficacy, safety and pharmacokinetics of Unecritinib (TQ-B3101) for patients with ROS1 positive advanced non-small cell lung cancer: a Phase I/II Trial

  2023cites this paper
• Identification of novel gene signature for lung adenocarcinoma by machine learning to predict immunotherapy and prognosis

  2023cites this paper
• A New Risk Score Model Based on Pyrogenic Signatures for the Prediction of Survival and Immune Microenvironment Features in Lung Adenocarcinoma

  2023cites this paper
• Factors Affecting 2-Year Survival in Patients With Non–Small Cell Lung Cancer Brain Metastases: Evidence from Indonesia’s National Cancer Center, Jakarta, Indonesia

  2023cites this paper
• The Effect of Chemotherapeutic Agents on Survival in Metastatic Non-Small-Cell Lung Cancer with KRAS Mutation

  2023cites this paper
• Advancing oncology drug therapies for sub-Saharan Africa

  2023cites this paper
• Prognostic significance of SH2D5 expression in lung adenocarcinoma and its relation to immune cell infiltration

  2023cites this paper
• Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non–Small Cell Lung Cancer in Taiwan

  2023cites this paper
• Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1(‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort

  2023cites this paper
• Drug resistance related genes in lung adenocarcinoma predict patient prognosis and influence the tumor microenvironment

  2023cites this paper
• The association between tyrosine kinase inhibitors and fatal arrhythmia in patients with non-small cell lung cancer in Taiwan

  2023cites this paper
• Chinese and Western Integrative Medicine for Stage IIIb-IVb Non-Small Cell Lung Cancer: Design and Rationale of a Multi-center, Prospective Registry (NSCLC-Chinese and Western Integrative Medicine cohort)

  2023cites this paper
• Aggressive Local Ablative Radiotherapy Mitigates Progression Risk in Oligometastatic Lung Adenocarcinoma

  2023cites this paper
• Effects of concurrent TP53 mutations on the efficacy and prognosis of targeted therapy for advanced EGFR mutant lung adenocarcinoma.

  2023cites this paper
• Integrating single-cell and bulk RNA sequencing to develop a cancer-associated fibroblast-related signature for immune infiltration prediction and prognosis in lung adenocarcinoma

  2023cites this paper
• Targeting lung cancer with clinically relevant EGFR mutations using anti-EGFR RNA aptamer

  2023cites this paper
• A retrospective study on the efficacy and safety of Endostar with chemotherapy in EGFR-TKI-resistant NSCLC

  2023cites this paper
• Investigating subtypes of lung adenocarcinoma by oxidative stress and immunotherapy related genes

  2023cites this paper
• Prognostic value of TLR from FDG PET/CT in patients with margin-negative stage IB and IIA non-small cell lung cancer

  2023cites this paper
• A-to-I edited miR-411-5p targets MET and promotes TKI response in NSCLC-resistant cells

  2023cites this paper
• Patient Characteristics, Testing and Treatment Patterns, and Outcomes in EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Multinational, Real-World Study

  2023cites this paper
• Favorable Conditions for the Detection of EGFR T790M Mutation Using Plasma Sample in Patients with Non-Small-Cell Lung Cancer

  2023cites this paper
• Molecular Characterization and Prognosis of Lactate-Related Genes in Lung Adenocarcinoma

  2023cites this paper
• Tumor MK2 transcript levels are associated with improved response to chemotherapy and patient survival in NSCLC.

  2023cites this paper
• Machine learning-based immune prognostic model and ceRNA network construction for lung adenocarcinoma

  2023cites this paper
• Identification of two molecular subtypes and a novel prognostic model of lung adenocarcinoma based on a cuproptosis-associated gene signature

  2023cites this paper
• Machine learning-based integration of CD8 T cell-related gene signatures for comprehensive prognostic assessment in lung adenocarcinoma

  2023cites this paper
• Racial disparities in cancer care, an eyeopener for developing better global cancer management strategies

  2023cites this paper